Quantum Private Wealth LLC Has $505,000 Holdings in Exact Sciences Corporation $EXAS

Quantum Private Wealth LLC lessened its position in Exact Sciences Corporation (NASDAQ:EXAS) by 53.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,238 shares of the medical research company’s stock after selling 10,748 shares during the quarter. Quantum Private Wealth LLC’s holdings in Exact Sciences were worth $505,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA acquired a new stake in Exact Sciences during the 2nd quarter valued at $157,805,000. Holocene Advisors LP boosted its position in shares of Exact Sciences by 189.5% in the second quarter. Holocene Advisors LP now owns 2,145,181 shares of the medical research company’s stock worth $113,995,000 after buying an additional 1,404,086 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Exact Sciences by 643.1% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,286,595 shares of the medical research company’s stock valued at $70,390,000 after buying an additional 1,113,459 shares in the last quarter. Norges Bank acquired a new position in Exact Sciences during the second quarter valued at $48,372,000. Finally, AQR Capital Management LLC lifted its stake in Exact Sciences by 73.3% in the 2nd quarter. AQR Capital Management LLC now owns 1,753,283 shares of the medical research company’s stock worth $93,169,000 after acquiring an additional 741,517 shares in the last quarter. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. William Blair cut Exact Sciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 20th. TD Cowen downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Robert W. Baird set a $105.00 price objective on shares of Exact Sciences in a research note on Thursday, November 20th. Barclays reiterated an “equal weight” rating and issued a $105.00 target price (up previously from $77.00) on shares of Exact Sciences in a research report on Thursday, November 20th. Finally, Citigroup cut shares of Exact Sciences from a “buy” rating to a “hold” rating in a report on Thursday, November 20th. One investment analyst has rated the stock with a Buy rating, twenty-one have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $91.00.

Exact Sciences Price Performance

NASDAQ EXAS opened at $103.43 on Monday. The company has a quick ratio of 2.17, a current ratio of 2.43 and a debt-to-equity ratio of 0.97. The stock has a market capitalization of $19.74 billion, a PE ratio of -94.03, a price-to-earnings-growth ratio of 2.35 and a beta of 1.42. Exact Sciences Corporation has a 12-month low of $38.81 and a 12-month high of $103.54. The company has a 50 day moving average price of $102.31 and a two-hundred day moving average price of $77.94.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.During the same quarter last year, the business posted ($0.06) EPS. The business’s quarterly revenue was up 23.1% compared to the same quarter last year. As a group, equities analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.